Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

New England Journal of Medicine

Volumn 363, Issue 26, 2010, Pages 2511-2521

  Preudhomme, Claude ^a   Guilhot, Joëlle ^b   Nicolini, Franck Emmanuel ^c   Guerci Bresler, Agnès ^d   Rigal Huguet, Françoise ^e   Maloisel, Frederic ^f   Coiteux, Valérie ^a   Gardembas, Martine ^g   Berthou, Christian ^h   Vekhoff, Anne ⁱ   Rea, Delphine ^j   Jourdan, Eric ^k   Allard, Christian ^l   Delmer, Alain ^m   Rousselot, Philippe ⁿ   Legros, Laurence ^o   Berger, Marc ^p   Corm, Selim ^q   Etienne, Gabriel ^r   Roche Lestienne, Catherine ^a   Eclache, Virginie ^s   Mahon, François Xavier ^t   Guilhot, François ^b   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CHU NANCY BRABOIS   (France)

^e CHU PURPAN   (France)

^f Service d'Onco hématologie   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h BREST UNIVERSITY HOSPITAL   (France)

ⁱ HÔTEL DIEU   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k DEPARTMENT OF NEUROLOGY   (France)

^l CENTRE HOSPITALIER DE MEAUX   (France)

^m REIMS UNIVERSITY HOSPITAL   (France)

ⁿ CENTRE HOSPITALIER DE VERSAILLES   (France)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^p UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^q CHU   (France)

^r INSTITUT BERGONIÉ   (France)

^s AVICENNE HOSPITAL   (France)

^t UNIVERSITÉ DE BORDEAUX   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; IMATINIB; PEGINTERFERON ALPHA2A; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; INFECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLISM; MUCOSA INFLAMMATION; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; QUANTITATIVE ANALYSIS; RASH; REAL TIME POLYMERASE CHAIN REACTION; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 78650625238     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1004095     Document Type: Article

References (32)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-3.
3. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-4.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
5. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
6. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
7. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
8. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054-61.
9. [Erratum, Leukemia 2010;24:1102.]
10. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alpha plus cy tarabine in newly diagnosed chronic mye loid leukemia. N Engl J Med 2003;349:1423-32.
11. Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003;102:4298-305. (Pubitemid 37494087)
12. Guilhot F, Roy L, Saulnier PJ, Guilhot J. Interferon in chronic myeloid leukaemia: past and future. Best Pract Res Clin Haematol 2009;22:315-29.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
14. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown, 1994:253-6.
15. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
16. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
17. Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009;23:1957-63.
18. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphiapositive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.
19. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
20. Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007;109:4016-9.
21. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926-35.
22. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
23. Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010;28:392-7.
24. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2009;28:398-404.
25. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010:363: 2260-70.
26. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;363:2251-9.
27. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86:726-36.
28. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukemia. Nature 2010;463:676-80.
29. Essers MA, Offner S, Blanco-Bose WE, et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature 2009;458:904-8.
30. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 2009;15:696-700.
31. Lipton JH, Khoroshko ND, Golenkov AK, et al. Phase II, randomized, multicenter, comparative study of peginterferon alfa-2a (40 kD) versus interferon alfa-2a (Roferon-A) in patients with treatmentnaïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 2007;48:497-505.
32. Michallet M, Maloisel F, Delain M, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronicphase chronic myelogenous leukemia: a phase III study. Leukemia 2004;18:309-15.